Business Advisory services                  Life Sciences Consulting                  Product Development                  ANDAs                  FTFs                  505 b 2 a                  Late Stage Assets                  Phase-II Trials                  Marketing Authorization’s                  Dossiers                  Site Transfers                  Scale ups                   Tail End Brands                  Technologies and Know-how                  Project Management                   Business Excellence & Six Sigma
With a cumulative experience of over 300 years and proven industry trail blazers in their respective fields, a team of global professionals have contributed to our successes In every project that we undertake.
We are a team of entrepreneurs united in providing to our clients the highest level of professional service. The Garphi team is known for its skill and persistence in identifying opportunities and overcoming obstacles to successfully conclude deals that benefit our clients. We are flexible, rapidly deployed and dedicated to helping companies achieve their business objectives. Some of the key people and associates:

  • Mr. Venkat KamalakarBundla
  • Mr. Venkat KamalakarBundla is the lead who ensures, we deliver on our promises.A B. Pharm (Hons) and MBA with an industry standing of over 24 years comprising of extensive and diverse experience (consulting, operations& general management), Venkat has demonstrated success in leadership roles and experience in working and supporting Business andR&Dof Pharmaceutical and Biotechnology companies globally. His Global and Leadership positions with increasingly progressive mandates, for several large pharmaceutical organizations played a vital role before he co-founded Garphi in 2007.Venkat is also the board member& adviser for a number ofLife Science companies in India, Europe and USA . Widely networked and travelled he brings to the table, a strong techno-commercial and operational expertise which is of immense value in deal-making. He has had extensive experience from being on both sides of the negotiation table in several multi- million dollar global deals.


  • Dr. Gilbert Wenzelis
  • Dr. Gilbert Wenzelis is a pharmacist with over 30 years of top management and consultancy experience in the worldwide healthcare industry. As a member of the Executive Committee of Novartis (2000-2002) he reported directly to Chairman and CEO Daniel Vasella. In this capacity, Dr. Wenzel was responsible within Novartis for Group-wide strategic planning, consulting and M&A. Prior to his position at Novartis; he was a senior partner (Director) with McKinsey (1985-2000). Later he also led the worldwide Competence Center Pharma/Healthcare of Roland Berger Strategy Consultants (2004-2005). Before entering the consultancy field he started his career in 1980 at Hoechst AG in various operational functions in the pharma division (now Sanofi Aventis). Between 2001 and 2004 Gilbert was the Executive Chairman of Equity4Life AG, a CHF 180 Mio biotech fund located in Zurich. He is also a co-founding member of two Swiss medical foundations (StiftungProstatakrebsforschung and StiftungIntegrierteMedikamentenver
    sorgung).


  • Rajiv Kapasi
  • A CA from ICAI, India and MBA, Mr. Kapasi has more than 17 years of experience in Consulting in the field of Strategy and M & A. He was associated until early 2010 with Jubilant Organosys as Head - Strategy and M & A, as a leader of the M&A team which, completed multiple international cross border M&A transactions in various fields spread over 5 years. Prior to his corporate experience, Mr. Kapasiworked for leading consulting firms like Arthur Andersen, Ernst & Young in New Delhi, Mumbai and Chicago, where he led several projects of risk consulting, market entry strategy, transaction advisory, operational strategy with wide experience with clients like Coca-Cola, Moser Baer, Aventis, Barista, Dominos. He was on the Board of Directors of Andhra Pradesh Paper Mills and has been instrumental in divesting the promoter’s stake to a US company. The total deal size as reported in the media was in excess of $ 400 Million.


  • Dr. Kumar Bhargava
  • A PhD in Pharmacy and an MBA, Dr. Bhargava has over twenty years of experience in both commercial and technical aspects of drug development. He has led the Strategic Innovation in External Research and Development Innovation group at Pfizer from 2009 - 2011. He was responsible for scouting new opportunities in multiple therapeutic areas and establishing collaborations with biotech firms. Prior to Pfizer he was Director of New Business and Strategy at Wyeth. In his role he led the efforts in Women’s Health Care franchise to find new opportunities to strengthen Wyeth’s portfolio. Dr. Bhargava also led the commercial team at Ortho Biotech, a Johnson & Johnson company. In that role he was responsible for scouting, evaluating and negotiating deals with other companies that may have technology that can be applied to increase the market share of Procrit, a US$4 billion oncology product. Dr. Bhargava was also responsible for developing multiple products at Procter & Gamble and at Abbott Labs.


  • Mr. MurliRamchandran
  • Mr. Ramchandran has more than 27 years of experience in manufacturing and services industries, including over 15 years in leadership roles, in both Indian and multinational organizations. He has demonstrated competencies at the strategic and the operating levels. Mr. Ramchandran is also skilled in senior management development as an accredited CEO and Executive Coach. He has held senior positions at - TVS Capital Funds Ltd as Executive Director;Sanmar Specialty Chemicals Ltd. as Managing Director; RPG Enterprises Limited as President-Business Improvement Strategy and IT; KPMG Consulting as Executive Director / Partner; Accenture as Associate Partner. Mr. Ramchandran has been on the boards of listed and unlisted entities and has an excellent track record in the areas of change management, strategy and performance improvement. A Mechanical Engineer (B.E. Hons) and Management (MMS) graduate from BITS, Pilani, he did his MS in Industrial Engineering from Columbia University, New York in the mid 80’s.


  • Mr. Bert Quint
  • Mr. Bert Quint has over 30 year experience in the health care industry. After starting at the UN – Board of Drugs & Narcotics, Bert soon moved to Abbott in the ‘80’s, with responsibility for AIDS diagnostics methods and transfusion medicine. After the successful stint at Abbott, Mr. Quint moved to Baxter, where he took responsibility for the Biotech division, focusing on blood products; from collection, preservation and fractionation to sales and marketing as well as expansion into New markets in Russia; covering central Eastern Europe, Africa, USA, Canada and Europe. Since the end of the 90’s he founded several companies in the healthcare field, covering innovative treatment methods in the field of interventional imaging, MRI, orthopedic solutions, cardiology, urology as well as pharmaceuticals encompassing NCEs, specialty and generic products. After graduating in biochemistry and applied sciences at the University of Brussels, Bert pursued Economics in Paris. Mr Bert Quint lectured at several medical faculties in Istanbul, Ankara and Moscow, and also has consulted various governmental agencies in several countries. Fluent in 5 languages and operating on a global turf; Bert has lived and worked in the US, Sweden, Greece, France, Belgium, Austria and now works out of Switzerland.


  • Dr. Maharaj K. Raina
  • A M.Pharm., Ph.D, he has over 40 years’ experience in the field of formulation development, quality control and production of pharmaceutical and cosmetic products, mainly products containing herbal and Ayurvedic ingredients as therapeutic agents. After a six year stint with Indian Council of Medical Research, Ministry of Health, New Delhi Dr. Raina has held increasingly broad R&D and operational roles in companies like Ranbaxy, Dabur&Lupin. He advises a number of Pharmaceutical companies. He is also been advising multi-lateral bodies like United Nations Industrial Development Organization (UNIDO), UNDP, International Union for Conservation of Natural Resources and Bio-diversity (IUCN) in the past. Dr. Raina is also an Advisory Panel Member for Botanicals, Dietary Supplements, Excipients Committee, United States Pharmacopoeia since 2006 and is also on the Editorial Board of Indian Drugs, Indian Journal of Pharmaceutical Sciences, Indian Journal of Natural Productsand Heritage Healing.


  • Dr. NeerajSrivastava
  • A Ph.D with a M.Sc. in Organic Chemistry and a P.G. Diploma in Business Management, Neeraj has excelled himself in technical services over the last 30 years. In addition to his core competencies in Quality Assurance and Quality Control, Neerajhas developed a good hands-off experience in technical and manufacturing operations. He has built an enviable track record in Projects, Manufacturing services, Regulatory affairs, Vendor development and Training at senior levels with different Pharma companies in his career span of 3 decades in both drug substance and drug products.